Áttétes emlőrák: vizsgálatok itt: Bulgária
7 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peoplePhase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Where
- Gabrovo, Plovdiv, Sofia, Sofiya
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- Relay Therapeutics, Inc.
See details and how to joinNCT06982521 · EU 2025-523083-21-00 - 3. fázisTaking peopleSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- Where
- Plovdiv, Sofia, Stara Zagora
- Életkor
- 18 év and over
- People
- 788 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06380751 · EU 2023-504180-16-00 - 3. fázisTaking peopleA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Where
- Burgas, Haskovo, Plovdiv, Shumen, Sofia, Sofiya
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Pfizer
See details and how to joinNCT07062965 · EU 2025-520566-22-00 - 3. fázisTaking peoplePhase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Where
- Burgas, Panagyurishte, Ruse, Sofia
- Életkor
- 18 év and over
- People
- 1180 worldwide
- Run by
- Celcuity Inc
See details and how to joinNCT06757634 · EU 2024-518933-28-01 - 2. fázisNot yet taking people in BulgáriaRoll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
- Where
- Sofia
- People
- 51 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07679269 · EU 2026-525890-38-00 - No phaseTaking peopleReal-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer
- Where
- Burgas, Panagyurishte, Plovdiv, Sofia, Stara Zagora, Varna
- Életkor
- 18 év and over
- People
- 138 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06727227 - 3. fázisNot yet taking people in BulgáriaA Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
- Where
- Dobrich, Haskovo, Sofia, Sofiya
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- Rovi Pharmaceuticals Laboratories
See details and how to joinNCT07340658 · EU 2025-524846-85-00